Market Valuation & Earnings Multiples
Market capitalization, P/E ratios, and enterprise value
Market Cap2.15B
Enterprise Value1.80B
RLAY
(NASDAQ)Relay Therapeutics, Inc.
$12.54-- (--)
Loading... - Market loading
Relay Therapeutics (RLAY) Key Statistics & Financial Metrics
Complete stock analysis with 40+ metrics: valuation ratios, profitability margins, financial health indicators, and dividend data.
Stock Valuation Metrics
Market value, earnings multiples, and pricing ratios
Price-Based Ratios
Valuation ratios based on stock price
Price/Sales (ttm)120.34
Forward Price/Sales78.42
Price/Book (mrq)3.26
Price/Tangible Book (mrq)3.26
Enterprise Value Ratios
EV-based valuation multiples
EV/Revenue116.99
EV/Earnings-6.50
EV/EBITDA-6.05
EV/EBIT-5.49
EV/FCF-7.62
Stock Price
Current price, 52-week range, and moving averages
Current Price$12.54
1-Day Change8.24%
52-Week High$11.49
52-Week Low$1.78
52-Week Change336.03%
YTD Change31.66%
1-Year Change332.53%
50-Day MA$9.24
200-Day MA$6.45
Avg Volume (30 day)8.89M
Share Statistics
Outstanding shares, float, and per-share metrics
Shares Outstanding171.59M
Book Value per Share$3.30
Net Cash per Share$0.47
FCF per Share$-1.37
Analyst Price Targets & Consensus
Wall Street analyst ratings and 12-month price targets (90 days)
Price Target$17.80
Target Upside/Downside41.95%
Analyst ConsensusStrong Buy
Analyst Count5
Profitability & Financial Performance
Profit margins, return metrics, and earnings analysis
Profit Margins
Profitability margins across income statement
Gross Margin91.23%
EBITDA Margin (ttm)-1934.08%
EBIT Margin (ttm)-2130.02%
Operating Margin (ttm)-1971.46%
Pretax Margin (ttm)-1800.46%
Profit Margin (ttm)-1800.46%
FCF Margin (ttm)-1535.98%
Return on Investment Metrics
ROE, ROA, ROIC, and capital efficiency ratios
Return on Equity (ttm)-48.76%
Return on Assets (ttm)-44.50%
Return on Invested Capital (ttm)-50.13%
Return on Capital Employed (ttm)-54.90%
Income Statement (TTM)
Trailing twelve months revenue and earnings
Revenue15.36M
Gross Profit14.01M
Operating Income-302.74M
Pretax Income-276.48M
Net Income-276.48M
EBITDA-297.00M
EBIT-327.09M
Diluted EPS$-1.61
Cash Flow (TTM)
Operating cash flow and free cash flow metrics
Operating Cash Flow-235.46M
Capital Expenditures410.00K
Free Cash Flow-235.87M
Growth Rates (YoY)
Year-over-year growth metrics
Revenue Growth53.45%
Financial Health & Dividends
Balance sheet analysis, debt ratios, and dividend metrics
Assets & Cash
Total assets and cash positions
Total Assets (mrq)621.33M
Cash & Securities (mrq)84.02M
Net Cash (mrq)80.25M
Net Cash per Share$0.47
Debt & Liabilities
Liabilities, debt, equity, and working capital
Total Debt (mrq)32.46M
Working Capital (mrq)552.70M
Total Equity (mrq)567.06M
Book Value per Share$3.30
Liquidity & Leverage
Liquidity, leverage, and debt coverage ratios
Current Ratio (mrq)22.61
Quick Ratio (mrq)22.61
Debt/Equity (mrq)0.06
Dividend History & Payout Analysis
Dividend yield, payout ratios, and growth metrics
Dividend per Share (TTM)$0.00
Dividend Yield0.00%
Yield Metrics
Earnings, FCF, buyback, and shareholder yields
Earnings Yield-14.96%
FCF Yield-12.76%
Buyback Yield0.00%
Total Shareholder Yield0.00%
Financial Health Scores
Risk assessment and quality metrics
Altman Z-Score15.25
Piotroski F-Score4/9
Frequently Asked Questions About Relay Therapeutics Statistics
What are the key financial metrics for RLAY?
Relay Therapeutics, Inc. (RLAY) statistics include 40+ financial metrics organized into valuation ratios (P/E, P/S, P/B, PEG), profitability margins (gross, operating, net), return metrics (ROE, ROA, ROIC), and financial health indicators. These are updated regularly based on the latest filings and market data.
What is RLAY's valuation analysis?
The valuation section covers market capitalization, earnings multiples like trailing and forward P/E, price-based ratios (P/S, P/B, Price/FCF), and enterprise value ratios (EV/EBITDA, EV/Revenue, EV/FCF). Compare these against sector averages to assess whether Relay Therapeutics is overvalued or undervalued.
How do I read RLAY's profitability ratios?
Relay Therapeutics's profitability is measured through profit margins (gross, EBITDA, operating, net) and return metrics (ROE, ROA, ROIC, ROCE). Higher margins indicate better cost control, while higher returns show efficient capital deployment. The income statement and cash flow sections provide the underlying revenue and earnings data.
What do RLAY's debt ratios indicate?
The financial health section shows Relay Therapeutics's leverage through debt-to-equity, debt-to-assets, debt-to-EBITDA, and debt-to-FCF ratios, plus liquidity via the current and quick ratios. Lower debt ratios and higher liquidity ratios generally indicate stronger financial stability and lower default risk.
What is RLAY's dividend analysis?
The dividend section covers Relay Therapeutics's dividend yield, payout ratios (earnings-based and FCF-based), year-over-year dividend growth, years of consecutive growth, ex-dividend and pay dates, and payment frequency. The yield metrics section also includes earnings yield, FCF yield, buyback yield, and total shareholder yield.